In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compugen Ltd.

https://www.cgen.com/

Latest From Compugen Ltd.

Gilead’s Trispecific Alliance With Merus Continues Its Push In Novel Cancer Tech

Deal Snapshot: Gilead adds to its pipeline of multispecific antibodies for cancer, while Merus gets a first partner for its trispecific platform.

Deals Business Strategies

Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer

The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.

Deals Cancer

Israeli Biopharma Leaders Focus On Near-Term Targets

Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.

Market Intelligence Innovation

BioBytes: Four Big Pharma Companies Cultivating AI-Based Start-ups

Through an Israeli innovation lab, four big pharma companies are fostering AI-driven start-ups to help solve industry problems.

Innovation Artificial Intelligence
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Evogene, Compugen USA, Inc, Neviah Genomics Ltd
UsernamePublicRestriction

Register